Literature DB >> 17691783

Systematic exploration of the structural features of yatakemycin impacting DNA alkylation and biological activity.

Mark S Tichenor1, Karen S MacMillan, John D Trzupek, Thomas J Rayl, Inkyu Hwang, Dale L Boger.   

Abstract

A systematic examination of the impact of the yatakemycin left and right subunits and their substituents is detailed along with a study of its unique three subunit arrangement (sandwiched vs extended and reversed analogues). The examination of the ca. 50 analogues prepared illustrate that within the yatakemycin three subunit structure, the subunit substituents are relatively unimportant and that it is the unique sandwiched arrangement that substantially increases the rate and optimizes the efficiency of its DNA alkylation reaction. This potentiates the cytotoxic activity of yatakemycin and its analogues overcoming limitations typically observed with more traditional compounds in the series (CC-1065, duocarmycins). Moreover, a study of the placement of the alkylation subunit within the three subunit arrangement (sandwiched vs extended and reversed analogues) indicates that it not only has a profound impact on the rate and efficiency of DNA alkylation but also controls and establishes the DNA alkylation selectivity as well, where both enantiomers of such sandwiched agents alkylate the same adenine sites exhibiting the same DNA alkylation selectivity independent of their absolute configuration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17691783      PMCID: PMC2519902          DOI: 10.1021/ja072777z

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  22 in total

1.  CC-1065 and the Duocarmycins: Synthetic Studies.

Authors:  Dale L. Boger; Christopher W. Boyce; Robert M. Garbaccio; Joel A. Goldberg
Journal:  Chem Rev       Date:  1997-05-08       Impact factor: 60.622

Review 2.  Mechanisms of in situ activation for DNA-targeting antitumor agents.

Authors:  Scott E Wolkenberg; Dale L Boger
Journal:  Chem Rev       Date:  2002-07       Impact factor: 60.622

3.  Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp.

Authors:  M Ichimura; T Ogawa; K Takahashi; E Kobayashi; I Kawamoto; T Yasuzawa; I Takahashi; H Nakano
Journal:  J Antibiot (Tokyo)       Date:  1990-08       Impact factor: 2.649

4.  Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065.

Authors:  M A Warpehoski; I Gebhard; R C Kelly; W C Krueger; L H Li; J P McGovren; M D Prairie; N Wicnienski; W Wierenga
Journal:  J Med Chem       Date:  1988-03       Impact factor: 7.446

5.  Molecular basis for sequence-specific DNA alkylation by CC-1065.

Authors:  L H Hurley; C S Lee; J P McGovren; M A Warpehoski; M A Mitchell; R C Kelly; P A Aristoff
Journal:  Biochemistry       Date:  1988-05-17       Impact factor: 3.162

6.  CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity.

Authors:  D G Martin; C Biles; S A Gerpheide; L J Hanka; W C Krueger; J P McGovren; S A Mizsak; G L Neil; J C Stewart; J Visser
Journal:  J Antibiot (Tokyo)       Date:  1981-09       Impact factor: 2.649

7.  Catalysis of the CC-1065 and duocarmycin DNA alkylation reaction: DNA binding induced conformational change in the agent results in activation.

Authors:  D L Boger; R M Garbaccio
Journal:  Bioorg Med Chem       Date:  1997-02       Impact factor: 3.641

8.  Yatakemycin, a novel antifungal antibiotic produced by Streptomyces sp. TP-A0356.

Authors:  Yasuhiro Igarashi; Katsuyuki Futamata; Tsuyoshi Fujita; Akira Sekine; Hisato Senda; Hideo Naoki; Tamotsu Furumai
Journal:  J Antibiot (Tokyo)       Date:  2003-02       Impact factor: 2.649

9.  Establishing the parabolic relationship between reactivity and activity for derivatives and analogues of the duocarmycin and CC-1065 alkylation subunits.

Authors:  Jay P Parrish; Terry V Hughes; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2004-01-14       Impact factor: 15.419

Review 10.  CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents.

Authors:  D L Boger; D S Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

View more
  22 in total

1.  Synthesis and evaluation of duocarmycin SA analogs incorporating the methyl 1,2,8,8a-tetrahydrocyclopropa[c]oxazolo[2,3-e]indol-4-one-6-carboxylate (COI) alkylation subunit.

Authors:  Kristopher E Boyle; Karen S MacMillan; David A Ellis; James P Lajiness; William M Robertson; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-02-02       Impact factor: 2.823

2.  A five-membered lactone prodrug of CBI-based analogs of the duocarmycins.

Authors:  Mika Uematsu; Daniel M Brody; Dale L Boger
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

3.  Synthesis and evaluation of a series of C5'-substituted duocarmycin SA analogs.

Authors:  William M Robertson; David B Kastrinsky; Inkyu Hwang; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-03-25       Impact factor: 2.823

4.  Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Douglas Brown; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2013-05-10       Impact factor: 7.446

5.  Asymmetric synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI).

Authors:  James P Lajiness; Dale L Boger
Journal:  J Org Chem       Date:  2010-12-30       Impact factor: 4.354

6.  Synthesis and characterization of a cyclobutane duocarmycin derivative incorporating the 1,2,10,11-tetrahydro-9H-cyclobuta[c]benzo[e]indol-4-one (CbBI) alkylation subunit.

Authors:  James P Lajiness; Dale L Boger
Journal:  J Am Chem Soc       Date:  2010-10-06       Impact factor: 15.419

7.  Synthesis and evaluation of a thio analogue of duocarmycin SA.

Authors:  Karen S MacMillan; James P Lajiness; Carlota Lopez Cara; Romeo Romagnoli; William M Robertson; Inkyu Hwang; Pier Giovanni Baraldi; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2009-10-17       Impact factor: 2.823

Review 8.  Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065.

Authors:  Karen S MacMillan; Dale L Boger
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

9.  Rational design, synthesis, and evaluation of key analogues of CC-1065 and the duocarmycins.

Authors:  Mark S Tichenor; Karen S MacMillan; James S Stover; Scott E Wolkenberg; Maria G Pavani; Lorenzo Zanella; Abdel N Zaid; Gianpiero Spalluto; Thomas J Rayl; Inkyu Hwang; Pier Giovanni Baraldi; Dale L Boger
Journal:  J Am Chem Soc       Date:  2007-10-19       Impact factor: 15.419

10.  Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers.

Authors:  George A Vielhauer; Megan Swink; Nikhil K Parelkar; James P Lajiness; Amanda L Wolfe; Dale Boger
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.